RE:Why a pharma-grade nutraceutical...Ceapro mgmt does not need to excessively "pump" the OBG pill or products in clinical trials. They are potentially lucrative endeavours but building shareholder expectations up in regards to these outcomes might backfire. Some shareholders might view these trials as an all or nothing vote on the companies potential. Ceapro has a number of opportunities with sizeable merit, just have to execute.
If regulatory agencies have given the green light to OBG with regards to health claims then Ceapro has a perfect opportunity in front of them with little risk. Given past company activity, I would assume that Ceapro has already built a presence and has deals in the works with customers in the beverage market, which is kind of a large.
While the pharma industry and scientists continue to debate the levels, types and methods for effectively managing cholesterol and cardiovascular health, Ceapro can work with a beverage maker and slap an "OBG Inside" label on a can of pop and sell it as heart healthy.